REDHILL BIOPHARMA LTD-SP ADR (RDHL)
US7574683014 - ADR
RDHL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. RDHL has a medium profitability rating, but doesn't score so well on its financial health evaluation. RDHL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RDHL was profitable.
RDHL had a negative operating cash flow in the past year.
RDHL had negative earnings in 4 of the past 5 years.
RDHL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RDHL's Return On Assets of 108.59% is amongst the best of the industry. RDHL outperforms 100.00% of its industry peers.
Looking at the Return On Equity, with a value of 39206.56%, RDHL belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Return On Invested Capital of RDHL (1261.60%) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 108.59% | ||
| ROE | 39206.56% | ||
| ROIC | 1261.6% |
ROA(3y)1.58%
ROA(5y)-18.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RDHL has a Profit Margin of 366.25%. This is amongst the best in the industry. RDHL outperforms 99.46% of its industry peers.
Looking at the Operating Margin, with a value of 193.45%, RDHL belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
With a Gross Margin value of 47.03%, RDHL perfoms like the industry average, outperforming 59.14% of the companies in the same industry.
RDHL's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 193.45% | ||
| PM (TTM) | 366.25% | ||
| GM | 47.03% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.3%
GM growth 5Y-6.56%
2. Health
2.1 Basic Checks
RDHL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, RDHL has more shares outstanding
Compared to 5 years ago, RDHL has more shares outstanding
Compared to 1 year ago, RDHL has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -23.99, we must say that RDHL is in the distress zone and has some risk of bankruptcy.
RDHL's Altman-Z score of -23.99 is on the low side compared to the rest of the industry. RDHL is outperformed by 88.71% of its industry peers.
A Debt/Equity ratio of 3.11 is on the high side and indicates that RDHL has dependencies on debt financing.
RDHL has a Debt to Equity ratio of 3.11. This is amonst the worse of the industry: RDHL underperforms 82.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -23.99 |
ROIC/WACC603.64
WACC2.09%
2.3 Liquidity
RDHL has a Current Ratio of 0.74. This is a bad value and indicates that RDHL is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.74, RDHL is not doing good in the industry: 94.62% of the companies in the same industry are doing better.
RDHL has a Quick Ratio of 0.74. This is a bad value and indicates that RDHL is not financially healthy enough and could expect problems in meeting its short term obligations.
RDHL has a Quick ratio of 0.56. This is amonst the worse of the industry: RDHL underperforms 93.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.56 |
3. Growth
3.1 Past
RDHL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 292.28%, which is quite impressive.
RDHL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -89.43%.
RDHL shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.82% yearly.
EPS 1Y (TTM)292.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-89.43%
Revenue growth 3Y-53.36%
Revenue growth 5Y-4.82%
Sales Q2Q%42.89%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, RDHL will show a very strong growth in Revenue. The Revenue will grow by 63.11% on average per year.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year131.11%
Revenue Next 2Y105.48%
Revenue Next 3Y77.82%
Revenue Next 5Y63.11%
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
RDHL is valuated cheaply with a Price/Earnings ratio of 0.00.
RDHL's Price/Earnings ratio is rather cheap when compared to the industry. RDHL is cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Earnings ratio of RDHL to the average of the S&P500 Index (27.28), we can say RDHL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RDHL indicates a rather cheap valuation: RDHL is cheaper than 98.39% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.02 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for RDHL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REDHILL BIOPHARMA LTD-SP ADR
NASDAQ:RDHL (1/14/2025, 8:02:11 PM)
5.506
-0.07 (-1.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners11.54%
Inst Owner Change82.03%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.05M
Analysts82.86
Price Target19380 (351879.66%)
Short Float %181.15%
Short Ratio0.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0 | ||
| Fwd PE | N/A | ||
| P/S | 1.08 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 115.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 0.02 |
EPS(TTM)2119.18
EY38488.56%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-18.92
FCFYN/A
OCF(TTM)-18.92
OCFYN/A
SpS5.1
BVpS0.05
TBVpS-4.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 108.59% | ||
| ROE | 39206.56% | ||
| ROCE | 1596.97% | ||
| ROIC | 1261.6% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 193.45% | ||
| PM (TTM) | 366.25% | ||
| GM | 47.03% | ||
| FCFM | N/A |
ROA(3y)1.58%
ROA(5y)-18.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.3%
GM growth 5Y-6.56%
F-Score4
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.11 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 0.24% | ||
| Cap/Sales | 0.03% | ||
| Interest Coverage | 168.43 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.56 | ||
| Altman-Z | -23.99 |
F-Score4
WACC2.09%
ROIC/WACC603.64
Cap/Depr(3y)1.22%
Cap/Depr(5y)126.92%
Cap/Sales(3y)0.21%
Cap/Sales(5y)17.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)292.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-89.43%
Revenue growth 3Y-53.36%
Revenue growth 5Y-4.82%
Sales Q2Q%42.89%
Revenue Next Year131.11%
Revenue Next 2Y105.48%
Revenue Next 3Y77.82%
Revenue Next 5Y63.11%
EBIT growth 1Y129.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.66%
OCF growth 3YN/A
OCF growth 5YN/A